








































Role of hyperpolarization-activated cyclic
nucleotide-gated ion channels in neuropathic pain:
a proof-of-concept study of ivabradine in patients
with chronic peripheral neuropathic pain
Shannon A. Bernard Healeya, Ingrid Scholtesa, Mark Abrahamsb, Peter A. McNaughtonc, David K. Menona,
Michael C. Leea,*
Abstract
Introduction: Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion channels mediate repetitive action potential firing in
the heart and nervous system. The HCN2 isoform is expressed in nociceptors, and preclinical studies suggest a critical role in
neuropathic pain. Ivabradine is a nonselective HCN blocker currently available for prescription for cardiac indications. Mouse data
suggest that ivabradine in high concentrations is equianalgesic with gabapentin. We sought to translate these findings to patients
with chronic peripheral neuropathic pain.
Objectives: We sought to translate these findings to patients with chronic peripheral neuropathic pain.
Methods:Weadopted an open-label design, administering increasing doses of ivabradine to target a heart rate of 50 to 60BPM, up
to a maximum of 7.5 mg twice daily. All participants scored their pain on an 11-point numerical rating scale (NRS).
Results: Seven (7) participants received the drug and completed the study. There was no significant treatment effect on the primary
endpoint, the difference between themean score at baseline and atmaximumdosing (mean reduction5 0.878, 95%CI522.07 to
0.31,P5 0.1). Exploratory analysis using linearmixedmodels, however, revealed a highly significant correlation between ivabradine
dose and pain scores (x2(1)5 74.6, P, 0.001), with a reduction of 0.126 0.01 (SEM) NRS points per milligram. The 2 participants
with painful diabetic neuropathy responded particularly well.
Conclusion: This suggests that ivabradine may be efficacious at higher doses, particularly in patients with diabetic neuropathic
pain. Importantly, participants reported no adverse effects. These data suggest that ivabradine, a peripherally restricted drug
(devoid of central nervous system side effects), is well tolerated in patients with chronic neuropathic pain. Ivabradine is now off-
patent, and its analgesic potential merits further investigation in clinical trials.
Keywords: Clinical trial, Hyperpolarization-activated cyclic nucleotide-gated channels, Ivabradine, Chronic pain, Diabetic
neuropathies
1. Introduction
Hyperpolarization-activated cyclic nucleotide-gated (HCN) ion
channels are important modulators of action potential rhythm and
frequency in the heart and nervous system.18,35 They carry an
inward current, named If in the heart and Ih in neurons.
18,35 The
HCN ion channel family comprises 4 isoforms, HCN1 to HCN4.
HCN1 and HCN3 are relatively insensitive to modulation by cyclic
AMP (cAMP), whereas in HCN2 and HCN4, the binding of cAMP
shifts the activation curve as a function of membrane voltage in
the positive direction and so increases the Ih current.
18,35 HCN4 is
expressed in pacemaker tissue in the heart and is responsible for
the cardiac pacemaker potential.18 HCN1 and HCN2 are
expressed in the central and peripheral nervous systems, where
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they are have a similar role in driving repetitive firing in
neurons.10,15,23,24,28,29,35 Small sensory neurons, the majority
of which are nociceptors, express a slow, cAMP-sensitive Ih
current, consistent with HCN2 expression.6,10,22,35 Upon tissue
injury, inflammatory mediators such as prostaglandin E2 are
released, which results in a rise in intracellular cAMP and an
increase in the rate of action potential firing.24 This mechanism is
Ih-dependent and therefore suggests that HCN2 may have a role
as a “pacemaker of pain.”12,24 Preclinical work in mouse models
of both inflammatory and neuropathic pain supports this role for
HCN2. Pharmacological blockade and targeted genetic deletion
of HCN2 channels reduced both in vitro nociceptor excitability
and in vivo behavioural measures of pain.7,11,22
Neuropathic pain is notoriously difficult to treat and is
associated with significant morbidity and mortality. Preclinical
work suggests that HCN2 may have a particularly important role
in neuropathic pain.6,9,11,17,19,31 In a sciatic nerve lesion model,
there was no enhanced sensitivity to heat, cold, or mechanical
stimuli in mice with a selective deletion of HCN2 in nociceptors.11
In a chemotherapy-induced neuropathy model, selective block-
ade of HCN1/HCN2 reduced neuronal excitability in vitro and
thermal hypersensitivity in vivo.9,31 Although there is currently no
HCN2-specific antagonist licenced for use in humans, ivabradine
is available as a nonselective HCN antagonist for the treatment of
chronic angina and heart failure. Ivabradine does not cross the
blood–brain barrier and is therefore devoid of central nervous
system (CNS) side effects which plague many current neuro-
pathic pain medications. In the same sciatic nerve injury and
chemotherapy-induced neuropathic pain models, ivabradine
was equianalgesic with gabapentin.45 We previously conducted
a crossover randomized controlled trial examining the effect of
ivabradine on capsaicin-induced pain in healthy human volun-
teers.20 There were no significant effects of the drug on
spontaneous pain or hyperalgesia. However, only a single 15-
mg dose of ivabradine was administered. In addition, capsaicin
causes neurogenic inflammation acutely, and the mechanisms
underlying chronic neuropathic may pain differ.44 Here, we report
the effects of ivabradine administered for at least 6 weeks in
patients with chronic peripheral neuropathic pain.
2. Methods
The study was conducted in accordance with the spirit and the
letter of the Declaration of Helsinki, the conditions and principles
of International Conference on Harmonization’s Good Clinical
Practice, and the protocol and applicable local regulatory
requirements and laws. The study was registered prospectively
(ISRCTN68734605), and ethical approval was obtained from the
London-Bromley Research Ethics Committee (16/LO/1901).
Written informed consent was obtained from every participant
before any study-related activity was performed.
2.1. Study design
This was a single-centre, open-label, feasibility study to assess the
effect of ivabradine on chronic peripheral neuropathic pain in
humans. Preclinical data suggest a strong dose–response re-
lationship for the effect of ivabradine on heart rate and pain.45
Maximal analgesia is achieved at higher doses, when the effect of
ivabradine on heart rate plateaus in humans.30,40 However, the risk
of cardiac side effects at high doses in patients with sensory or
autonomic neuropathies is unknown; using a fixedmaximum dose
designmay have led to adverse events and participant withdrawal.
To avoid this, we adopted an open-label design in which dose
could be increased incrementally, titrating to heart rate and
subjective symptoms. We additionally included a washout period
after dosing to increase the sensitivity of the exploratory analyses.
This dose–response design optimises detection of analgesic effect
while ensuring the participants’ safety.
2.2. Participants
Potential participants were identified from specialist clinics in
Addenbrooke’s Hospital and local general practices. We pro-
vided respondents with a participant information sheet and
invited them for a screening visit at the Addenbrooke’s Centre of
Clinical Investigation in Cambridge. The following assessments
were recorded as part of screening (visit 1, Fig. 1): clinical history,
physical examination, medication use, and 12-lead electrocar-
diogram (ECG). We used Douleur Neuropathique 4 (DN4) and
quantitative sensory testing (QST) to ascertain the neuropathic
nature of pain and the 36-Item Short-Form Survey (SF-36) to
assess overall health status.4,42
Participants had to have had a diagnosis of peripheral
neuropathy with pain for over 6 months which scored more than
4 on the DN4, a scoring matrix for pain with neuropathic qualities
in the history and on clinical examination. Participants with any
significant cardiac comorbidity were excluded. The participant
inclusion and exclusion criteria are shown in Table 1. All
participants who met the eligibility criteria and gave written
informed consent were included.
2.3. Dosing
The active treatment consisted of oral ivabradine, dosed at
between 2.5 mg and 7.5 mg twice daily. The starting dose was
2.5 mg and was incrementally increased after a review of adverse
effects and ECGmonitoring at clinic visits every 2 to 3 weeks, to a
maximumof 7.5mg or a heart rate of 50 to 60BPM (Fig. 1). This is
a similar dosing schedule for the treatment of stable angina,
which is started at 5 mg and increased to 7.5 mg twice daily.13
2.4. Study assessments
Participants reported pain on an 11-point numerical rating scale
(NRS) (05 no pain; 105 worst possible pain) implemented on a
short message service (FAST, Cambridge Digital Health).
Participants were instructed and reminded to rate pain whose
qualities are neuropathic in nature (as described by the adjectives
in the DN4 questionnaire) and which was localised to the affected
site. Daily text-based reminders were sent at a time of the
participant’s choosing. They were also allowed to send in ratings
ad libitum. This was set up at screening and continued
throughout the study.
At study visits 2 to 6, we administered the following question-
naires to capture the secondary outcome measures for chronic
pain: brief pain inventory,1,38 Insomnia Severity Index (ISI),2 Pain
Disability Index,37 and Depression, Anxiety, and Positive Outlook
Scale.26 TheNeuropathic PainSymptom Inventory andQSTon the
affected area were used to assess the neuropathic characteristics
of thepain.5,32Quantitative sensory testingpunctatepain threshold
was taken as themean of theweight atwhich pain is felt when a set
of 7 standardized punctate probes (8–512 mN in weight) were
applied in ascending and descending series. Quantitative sensory
testing dynamic allodynia was measured as the perceived pain,
rated from0 to100,when a standardized soft brushwas applied as
a single 2-cm stroke. For both measures, there was a minimum
stimulus interval of 10 seconds.
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2.5. Endpoints
The primary endpoint was the change from baseline inmean daily
NRS pain score after dosing. The baseline mean was themean of
all daily NRS pain scores before dose initiation. The treatment
mean was the mean of all daily NRS pain scores in the 10 days
before ivabradine cessation at visit 5. This ignores entries in the
first 4 days after dose adjustment, allowing ivabradine to reach
steady state in the plasma.34 The secondary endpoints were the
change from baseline in mean scores for each of the other
measures listed in the previous section. The score at dose
initiation was taken as baseline; the score at dose cessation (visit
5) was taken as treatment. Exploratory endpoints included
examining the above measures for treatment vs washout,
differences in baseline characteristics and individual participants’
pain diagnoses, and using ECG heart rate measurements to
explain variation in the primary and secondary endpoints.
2.6. Sample size calculation
We wanted to power for biologically significant or clinically useful
effects that are unlikely to be explained by placebo-based
analgesia. Placebo effects are well established, and Cochrane
meta-analyses have estimated that the placebo-based reduction
of pain scores is a standardized mean difference of 20.23 (95%
CI 20.28 to 20.17).14 These analyses suggest that placebo-
based analgesia would be expected to achieve a 1-point
reduction on an 11-point NRS. Hence, we chose to power for a
greater than 1-point NRS reduction; the null hypothesis was that
the mean reduction in pain score is less than 1. Initial calculations
suggested 36 participants would be required to correctly reject
the null hypothesis at 80% power and a type 1 error rate of 5%.
2.7. Statistical analysis
We used OpenClinica (Community Edition) to capture data
electronically and R Studio (Version 1.3.1093) to conduct
statistical testing and generate graphs.27,33 Continuous outcome
variables were summarized using the descriptive statistics n,
mean, SD. The primary and secondary endpoints were analysed
with 2-tailed dependent t tests comparing baseline mean with
treatment mean, as per the protocol. To determine whether the
effect of the drug on pain outlasts its presence in plasma, we ran
2-tailed dependent t tests comparing treatment mean with
washout mean as exploratory analyses.
Participants provided at least 1 daily NRS pain score
throughout the study period, producing a data set that was not
fully used by the primary endpoint analysis. Using all available pain
scores from each individual, we explored the effects of ivabradine
dose and time on daily NRS pain scores in a linear mixed effects
model.3 The fixed effects were dose and time; the random effect
was participant level. Mixed effects models are well suited to
longitudinal data because they take into account the correlated
Figure 1. Schematic of trial design. This was a single-arm design in which all participants went through a schedule of baseline (Baseline), incrementally increasing
dose (Treatment), and drug washout (Washout) periods. Participants rated their daily numerical rating scale (NRS) pain score in a pain diary. Secondary measures
were recorded at visits 2 to 6, shown as teal circles.
Table 1
Summary of inclusion and exclusion criteria for study participants.
Inclusion criteria Exclusion criteria
Be able to give voluntary written consent Known allergy to ivabradine; pre-existing treatment with ivabradine
Be aged 18 years or older Use of drugs known to interact with ivabradine; use of prohibited concomitant
analgesia; use of recreational drugs or excess alcohol
Have a diagnosis of peripheral neuropathy with pain, with
pain for $6 mo and a DN4 score $4 and NRS score $4
Scheduled for any clinical treatment (surgical, pharmacological, interventional, and
psychological) to begin during the trial
Be registered with a general practitioner Be unwilling for the general practitioner to be notified
Have the following ECG characteristics: normal sinus rhythm,
PR# 210, QTcB# 430 (men)# 450 (women), QRS# 120,
heart rate $60 beats per minute
Significant cardiovascular comorbidity,* including heart failure, severe cardiac
conduction abnormality, or postural hypotension
Significant renal or hepatic impairment†
Pregnancy, breastfeeding, or unwillingness to use contraception during the trial (both
men and women)
* The full list of proscribed cardiovascular comorbidities can be found in the supplementary material, available at http://links.lww.com/PR9/A134.
† The full list of proscribed thresholds for renal and hepatic function can be found in the supplementary material, available at http://links.lww.com/PR9/A134.
NRS, numerical rating scale.
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nature of repeated measures from the same subject and can
account for multiple factors that may affect the measures
differently over time. In addition, they can handle missing or
imbalanced data, as is the case here where participants did not
provide the same number of pain ratings per day.8,25
3. Results
The study was discontinued because of challenges to recruitment.
Data from individuals who completed the study are presented.
From a pooled general practice population of 90,000, we identified
and invited 201 patients. Twenty-five subjects attended the
screening visit; of those, 7 were eligible. These 7 completed the
study schedule as described in a 17-month period beginning in July
2017. One participant (subject 24) did not attend a follow-up visit,
but continued to submit NRS pain scores in the washout period so
was still included. Baseline characteristics are shown in Table 2.
3.1. Effect of ivabradine onprimary and secondary endpoints
Descriptive statistics for each outcomemeasure at baseline, at the
end of treatment, and the washout period are shown in Table 3,
top panel. There was no significant treatment effect on the primary
endpoint, the change from baseline in mean NRS pain score with
treatment: difference 5 20.878, 95% CI 5 22.07 to 0.31, P 5
0.100 (Table 4). Post hoc sensitivity analysis using a power of 0.80
and alpha of 0.05 indicated that with a sample of 7, we were
powered to detect a reduction in mean NRS of 2.20. There was a
significant treatment effect on 1 secondary endpoint, the change
from baseline in mean ISI score with treatment: difference 5
20.457, 95% CI 5 21.42 to 27.72, P 5 0.012 (Table 4).
Exploratory analysis of the difference between the end of treatment
and washout scores for each primary and secondary outcome
measure did not reveal any significant treatment effects (Table 4).
3.2. Effect of ivabradine on heart rate
Analysis of the effect of ivabradine on heart rate revealed a
significant effect when comparing baseline and treatment
(difference 5 212.29, 95% CI 5 25.62 to 218.95, P 5 0.004),
treatment and washout (difference 5113.71, 95% CI5 2.99 to
24.44, P 5 0.020), and when using a linear regression model to
assess the effect of dose on heart rate (F(1,39)5 10.4,P5 0.003,
R2 5 0.21). Individual participant heart rate data are shown in
Figure 2.
3.3. Effect of ivabradine on individual daily numerical rating
scale pain scores
The raw daily NRS pain score data for each subject are shown in
Figure 3, for interest. We conducted exploratory, hypothesis-
generating analysis using a linear mixed effects model with
dose and time as fixed effects and participant as a random
effect; this allows the intercepts for putative linear relationships
between dose, time, and NRS to vary by participant. This
accounts for the difference in baseline NRS pain scores
between participants. The analysis revealed a highly significant
relationship between ivabradine dose and daily NRS pain
scores (x2(1) 5 74.6, P , 0.001), with a reduction of 0.12 6
0.01 (SEM) NRS points per milligram of ivabradine, and a
significant relationship between time and daily NRS pain score
((x2(1) 5 74.6, P 5 0.012), with an increase of 0.004 6 0.002
(SEM) NRS points per trial day.
3.4. Adverse effects of ivabradine
The dosing schedule of ivabradine was very well tolerated in the
participants. Only 1 participant reported dizziness on the 7.5-mg
dose, which resolved spontaneously with no residual effects.
None of the participants reported luminous visual phenomena, a
recognised side effect of ivabradine.40
4. Discussion
The role of HCN2 ion channels in nociceptor firing is now well
established. Preclinical work using pharmacological blockade and
targeted genetic deletion has demonstrated they are required for
inflammatory and neuropathic pain.6,7,9,11,12,17,19,22,31,45 Accord-
ingly, peripherally restricted HCN2 blockers devoid of adverse
effects on the heart and CNSwould be highly desirable. Until these
are developed, we have ivabradine, a nonselective, peripherally
restrictedHCNblocker that is already clinically available. Preclinical
work has shown that ivabradine has analgesic properties in
behavioural and electrophysiological studies of neuropathic
pain.9,45 We sought to translate these findings to patients with a
diagnosis of peripheral neuropathic pain.
The primary endpoint for the studywas the difference inmean of
NRS scores obtained 10 days before the final treatment visit
compared with baseline mean. For this endpoint, there was no
significant analgesic effect of ivabradine. However, we failed to
achieve the sample size required because of challenges to
recruitment in a single centre. This was despite recruitment from
both the secondary carepain service and aprimary care population
of almost 100,000 patients. In addition, during the study, wemade
substantial amendments (approved by ethical, scientific, and
safety review) to increase reimbursement for travel to recruit
beyond the local area, broaden inclusion criteria to include
idiopathic neuropathic pain, and relax the ECG QTcB exclusion
criteria, based on safety data from our previous trial.17 These
recruitment challenges eventually led us to discontinue the trial,
and hence,wewere unpowered for the primary endpoint. Post hoc
sensitivity analysis suggested that with n 5 7, we were only
powered to detect an effect of 2.2 reduction in NRS pain score.
Although we did not detect any significant analgesic effect of
ivabradine, there was a dose-dependent reduction in participants’
heart rate. This is unsurprising, given that the slowing of heart rate is
an established drug effect.13 This finding usefully indicates that the
participants adhered to the dosing schedule, excluding non-
compliance as a cause for the negative study.
Data in mice suggest that the analgesic effect of ivabradine is
also dose-dependent, with approximately the same ED50 for
heart rate and analgesia at 2 to 2.5 mg/kg.45 This is consistent
with ivabradine blocking nociceptor HCN2 channels and
cardiac HCN4 channels approximately equally.36 Our previous
human trial of ivabradine in acute capsaicin-induced pain also
identified a robust dose-dependent reduction in heart rate, but
no significant analgesic effect.20 That trial used a single dose in
healthy participants under observation, so a dose of 15 mg was
used, twice the upper dose used here. At approximately 0.2
mg/kg and 0.1 mg/kg, respectively, these are more than 10
times lower than the indicative analgesic ED50 in mice. In this
study of peripheral neuropathic pain, incremental doses of
ivabradine were used in periods that varied between 2 and 3
weeks between participants (Fig. 3). We were therefore able to
explore ivabradine dose–response in a linear mixed effects
model, by using all the pain ratings provided by the 7
participants during the study. We found a highly significant
but modest effect of ivabradine dose on NRS pain score (0.12
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NRS points reduction per milligram, P, 0.001), suggesting we
would need to use at least 10 mg twice daily to see an effect
above what would be expected with placebo analgesia. It is
important to acknowledge that this finding is primarily driven by
data from 2 participants (Fig. 3). Interestingly, although the
study recruited from a range of aetiologies for peripheral
neuropathic pain, we note that the 2 participants who
responded are the 2 with painful diabetic neuropathy. In mouse
models of both type I and type II diabetic neuropathy, high-dose
ivabradine (5 mg/kg) had a profound effect on pain, reducing
mechanical pain thresholds back to baseline (before the
induction of diabetes).39 Diabetes is the leading cause of
peripheral neuropathy worldwide, and when surveyed, be-
tween 13% and 34% of these patients report significant pain.16
It is important not to overinterpret the observations from just 2
patients, but this apparent analgesic effect in cases of painful
diabetic neuropathy may merit further study.
The heterogeneity in neuropathic aetiology is 1 potential explana-
tion for the negative result; we did not observe a large analgesic
response in the patients with nondiabetic pain. However, although
there may be particular benefit in diabetic neuropathy, the preclinical
data demonstrate the role of HCN channels and analgesic effect of
Table 2
Baseline characteristics of the participants receiving ivabradine for chronic peripheral neuropathic pain.
















Concomitant analgesia Other medication
1 Male 55 27.6 113 Diabetic 4 10 15 56 10 N/A Insulin SC 15 IU daily
2 Male 66 38.4 68 Diabetic 6 50 45 96 70 Naproxen 500 mg OD and
duloxetine 30 mg OD
Metformin 500 mg BD,
allopurinol 300 mg OD,
atorvastatin 20 mg OD, and
omeprazole 20 mg OD
6 Male 49 26.2 87 Amputation 7 0 40 60 70 Gabapentin 1200 mg TDS,
amitriptyline 20 mg OD, and
paracetamol 1 g PRN
11 Male 66 21.8 71 Idiopathic 3 80 55 48 45 Gabapentin 900 mg TDS and
Amitriptyline 10 mg OD
Cholecalciferol 800 mg OD
17 Female 44 33.1 90 Chemotherapy 8 20 20 84 50 Duloxetine 60 mg OD,
paracetamol 1 g QDS,
pregabalin 300 mg BD, and
oramorph 10 mg 4 hrly
Omeprazole 20 mg BD,
pyridoxine 50 mL TDS,
tamoxifen 20 mg OD, zopiclone
3.75 mg OD, hypromellose 10
mcl PRN, and Hylo-Forte 1 drop
QDS
21 Male 77 37.3 81 Idiopathic 8 60 40 72 50 Gabapentin 300 mg QDS and
ibuprofen 400 mg OD
Allopurinol 400 mg OD,
mometasone 50 mcg OD, and
rabeprazole 20 mg BD
24 Male 64 25.6 71 Prolapsed disc 6 95 85 88 90 N/A Montelukast 10 mg OD, Clenil
Modulite 100 mcg BD,
lansoprazole 15 mg OD,
candesartan 8 mg OD,
amlodipine 5 mg OD, salbutamol
100 mcg BD, and rosuvastatin 5
mg OD
BD, twice daily; BMI, body mass index; DN4, Douleur Neuropathique 4; ECG rate, electrocardiogram heart rate; IU, insulin units; OD, once daily; PRN, as required; QDS, four times daily; SC, subcutaneous; SF-36, Short-Form 36
Health Status Questionnaire; TDS, three times daily.
Table 3
Descriptive statistics for primary and secondary outcome measures at baseline, during treatment, and after washout.
Outcome Baseline mean (SD) Treatment mean (SD) Washout mean (SD)
NRS, mean daily 5.39 (1.24) 4.52 (2.11) 5.48 (1.46)
BPI 5.11 (1.50) 4.21 (1.99) 5.21 (1.72)
ISI 12.29 (7.41) 7.71 (6.42) 8.43 (5.59)
NPSI 26.14 (13.84) 24.57 (19.61) 32.29 (18.84)
PDI 29.14 (20.98) 21.57 (23.50) 24.57 (21.48)
DAPOS depression 7.43 (2.37) 8.71 (4.07) 8.00 (2.52)
DAPOS anxiety 4.71 (2.14) 3.43 (0.53) 4.29 (1.50
DAPOS positive 8.86 (3.48) 8.00 (4.00) 8.00 (3.83)
QST-PPT 107.05 (132.03) 127.94 (134.04) 101.95 (124.07)
QST-DAS 6.54 (8.19) 3.91 (5.26) 10.91 (11.56)
Mean (SD).
BPI, brief pain inventory; DAPOS, Depression, Anxiety, and Positive Outlook Scale; DAS, Dynamic Allodynia Score; ISI, Insomnia Severity Index; NPSI, neuropathic pain symptom inventory; NRS, numerical rating scale pain
score; PDI, Pain Disability Index; PPT, punctate pain threshold; QST, quantitative sensory testing.
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ivabradine across neuropathic aetiologies, including traumatic nerve
lesions and chemotherapy-induced neuropathy. Another potential
confounder is the variation in medication use at baseline. Participants
taking any drugs on the British National Formulary’s ivabradine
interaction information were excluded; this includes inducers and
inhibitors of cytochrome P450 3A4, the enzyme responsible for the
metabolism of ivabradine, reducing the potential for pharmacokinetic
interaction from heterogenous concomitantmedications.40 The effect
of concomitant analgesia is more difficult to quantify and control for.
Twopatients reported no concomitant analgesia. To reduce the effect
of this, patients were required to keep their daily concomitant
analgesia the same throughout the trial.
Acknowledging the limitations of the exploratory analysis and very
small sample size, our findings suggest that a higher dosebeyond15
mg daily is required for clinically evident analgesic effect. In healthy
humans, a 20-mg daily dose of ivabradine for 5 days causes a 17%
to 20% reduction in heart rate, which is asymptomatic.30 There are
also safety data suggesting a trend towards a plateau effect on heart
rate at higher doses, with reduced risk of symptomatic bradycar-
dia.40 In this feasibility study, for safety reasons, we titrated dose to
heart rate up to the maximum of 15 mg daily as allowed in the
licenced posology of the drug. This meant the trial was necessarily
open label. Open-label studies are subject to a high risk of bias from
both the participants and the clinicians. In addition, we acknowledge
Table 4
Two-tailed dependent t tests comparing the primary and secondary outcome measures for baseline and treatment, and treatment and
washout, periods.
Outcome Baseline vs treatment Treatment vs washout
Difference 95% CI P Difference 95% CI P
NRS, mean daily 20.88 22.07 to 0.31 0.100 0.97 20.21 to 2.14 0.090
BPI 20.89 22.03 to 0.25 0.104 1.00 20.33 to 2.33 0.115
ISI 24.57 21.42 to 27.72 0.012 0.71 21.53 to 2.96 0.466
NPSI 21.57 214.70 to 11.56 0.780 7.71 24.08 to 19.51 0.161
PDI 27.57 216.57 to 1.42 0.085 3.00 228.44 to 34.44 0.823
DAPOS depression 1.29 22.16 to 4.73 0.397 20.71 24.04 to 2.61 0.618
DAPOS anxiety 21.29 NA 0.098 0.86 NA 0.203
DAPOS positive 20.86 22.50 to 0.78 0.248 0.00 22.67 to 2.67 1.000
QST-PPT 20.89 NA 0.438 225.99 NA 0.844
QST-DAS 22.63 NA 0.181 7.00 NA 0.100
For outcomes in which the distributions were not normal (by the Shapiro–Wilk test), a Wilcoxon test was used, which does not report confidence intervals.
BPI, brief pain inventory; CI, confidence interval; DAPOS, Depression, Anxiety, and Positive Outlook Scale; DAS, Dynamic Allodynia Score; ISI, Insomnia Severity Index; NPSI, neuropathic pain symptom inventory; NRS, numerical
rating scale pain score; PDI, Pain Disability Index; QST, quantitative sensory testing; PPT, punctate pain threshold.
Figure 2. ECG-derived heart rate for each participant. The point ranges show mean and SD, for baseline, treatment, and washout. Baseline heart rate for each
participant is themean of both predosing ECG heart rate values ([V11 V2]/2). The significance bars refer to t tests conducted on thesemean values, when *,0.05
and **,0.01. Also shown is an indication of ivabradine dose between the study visits. †Please note 1 participant, 24, failed to reachmaximumdosing of 7.5mg and
hence received 5 mg until dose cessation.
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the lack of placebo or control arm. Hence, both group and individual
results should be taken as exploratory in nature. Notably, there were
noadverse effects. Therefore,we recommend that these exploratory
results are further investigated in randomised, placebo-controlled
trials. In that regard, placebo effects driven by positive expectations
of benefit are highly pertinent in human trials and can be substantial
in pain medicine.21 These effects seem to have increased over time
in theUnitedStates.41 There are also data to suggest that open-label
placebos, in which participants are placebo-aware, still have
analgesic effects.43
Chronic neuropathic pain remains extremely difficult to
manage and places a great burden on individuals, their families
and carers, and society as a whole. Here, we report the first
human trial of ivabradine for chronic pain. Exploratory analysis of
our data suggests there may be an analgesic effect of ivabradine
at higher doses, particularly in diabetic neuropathic pain. Our
experience indicates that unlike current drugs for neuropathic
pain, ivabradine is very well tolerated and devoid of CNS side
effects. Furthermore, the drug is now off-patent. We believe that
placebo-controlled studies are warranted to ascertain ivabra-
dine’s analgesic potential, investigating currently licenced doses
in painful diabetic neuropathy, or higher doses in patients who
have neuropathic pain but are otherwise healthy.
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